Amerika Serikat - Inggris - NLM (National Library of Medicine)

tya pharmaceuticals - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 10 mg - fluoxetine capsules, usp are indicated for the acute and maintenance treatment of major depressive disorder in adult patients and in pediatric patients aged 8 to 18 years the usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should periodically be re-evaluated . [see ]. clinical studies (14.1) [see ] dosage and administration (2.1) fluoxetine capsules, usp are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with obsessive compulsive disorder (ocd) the effectiveness of fluoxetine capsules, usp in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. therefore, the physician who elects to use fluoxetine capsules, usp for extended periods should periodically re-evaluate the long-term usefulness

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

niche generics ltd - fluoxetine hydrochloride - oral capsule - 20mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - fluoxetine hydrochloride - oral capsule - 20mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - fluoxetine hydrochloride - oral capsule - 20mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - fluoxetine hydrochloride - oral capsule - 20mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

fannin (uk) ltd - fluoxetine hydrochloride - oral capsule - 20mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - fluoxetine hydrochloride - oral capsule - 20mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - fluoxetine hydrochloride - oral capsule - 20mg

Amerika Serikat - Inggris - NLM (National Library of Medicine)

redpharm drug, inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 20 mg - fluoxetine is indicated for the treatment of: acute and maintenance treatment of major depressive disorder [see clinical studies (14.1)]. acute and maintenance treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd) [see clinical studies (14.2)]. acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe bulimia nervosa [see clinical studies (14.3)]. acute treatment of panic disorder, with or without agoraphobia [see clinical studies (14.4)]. fluoxetine and olanzapine in combination is indicated for the treatment of: acute treatment of depressive episodes associated with bipolar i disorder. fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar i disorder. when using fluoxetine and olanzapine in combination, also refer to the clinical studies section of the package insert for symbyax®. when using fluoxetine capsules and olanzapine in combination, also re

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluoxetine hydrochloride, quantity: 22.36 mg (equivalent: fluoxetine, qty 20 mg) - tablet, dispersible - excipient ingredients: magnesium stearate; crospovidone; maize starch; saccharin sodium; microcrystalline cellulose; colloidal anhydrous silica; flavour - indications as at 4 september 2002 : indicated for the treatment of major depression. obsessive compulsive disorder (ocd). premenstrual dysphoric disorder (pmdd) as defined by the diagnostic and statistical manual fourth edition (dsm-iv) criteria. the essential features of pmdd, according to the dsm-iv, include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.